TY - JOUR
T1 - Seroprevalence and durability of rubella virus antibodies in a highly immunized population
AU - Crooke, Stephen N.
AU - Haralambieva, Iana H.
AU - Grill, Diane E.
AU - Ovsyannikova, Inna G.
AU - Kennedy, Richard B.
AU - Poland, Gregory A.
N1 - Funding Information:
Dr. Poland is the chair of a Safety Evaluation Committee for novel non-rubella investigational vaccine trials being conducted by Merck Research Laboratories. Dr. Poland offers consultative advice on vaccine development to Merck & Co. Inc., Avianax, Adjuvance, Valneva, Medicago, Sanofi Pasteur, GlaxoSmithKline, and Emergent Biosolutions. Drs. Poland and Ovsyannikova hold three patents on measles and vaccinia peptide research. Dr. Kennedy holds a patent on vaccinia peptide research. Dr. Kennedy has also received funding from Merck Research Laboratories to study waning immunity to mumps. All other authors declare no competing financial interests. These activities have been reviewed by the Mayo Clinic Conflict of Interest Review Board and are conducted in compliance with Mayo Clinic Conflict of Interest policies. This research has been reviewed by the Mayo Clinic Conflict of Interest Review Board and was conducted in compliance with Mayo Clinic Conflict of Interest policies.
Funding Information:
We would like to thank the staff of the Mayo Clinic Vaccine Research Group and all of the participants in this study. We would also like to thank Caroline L. Vitse for editorial assistance with the preparation of this manuscript. The work reported was funded by the National Institutes of Health under Award Number R37AI048793. The Mayo Clinic Biobank was supported by funding from the Mayo Clinic Center for Individualized Medicine. Dr. Poland is the chair of a Safety Evaluation Committee for novel non-rubella investigational vaccine trials being conducted by Merck Research Laboratories. Dr. Poland offers consultative advice on vaccine development to Merck & Co. Inc. Avianax, Adjuvance, Valneva, Medicago, Sanofi Pasteur, GlaxoSmithKline, and Emergent Biosolutions. Drs. Poland and Ovsyannikova hold three patents on measles and vaccinia peptide research. Dr. Kennedy holds a patent on vaccinia peptide research. Dr. Kennedy has also received funding from Merck Research Laboratories to study waning immunity to mumps. All other authors declare no competing financial interests. These activities have been reviewed by the Mayo Clinic Conflict of Interest Review Board and are conducted in compliance with Mayo Clinic Conflict of Interest policies. This research has been reviewed by the Mayo Clinic Conflict of Interest Review Board and was conducted in compliance with Mayo Clinic Conflict of Interest policies.
Funding Information:
We would like to thank the staff of the Mayo Clinic Vaccine Research Group and all of the participants in this study. We would also like to thank Caroline L. Vitse for editorial assistance with the preparation of this manuscript. The work reported was funded by the National Institutes of Health under Award Number R37AI048793 . The Mayo Clinic Biobank was supported by funding from the Mayo Clinic Center for Individualized Medicine .
Publisher Copyright:
© 2019 Elsevier Ltd
PY - 2019/6/27
Y1 - 2019/6/27
N2 - Background: Although the administration of the measles-mumps-rubella (MMR) vaccine has been widespread in the United States for decades, gaps in vaccine coverage still persist for various reasons. The maintenance of herd immunity against rubella virus (RV) is important to controlling the spread and resurgence of rubella and congenital rubella syndrome. Methods: In this study, we sought to assess the seroprevalence of RV-specific antibodies in an adult population from a defined geographic area in Olmsted County, MN, and the surrounding municipalities, with relatively high vaccine coverage and no documented evidence of circulating RV in the past 24 years. Rubella-specific IgG antibodies were measured by ELISA in a large set of serum samples (n = 1393) obtained from the Mayo Clinic Biobank. This cohort was 80.2% female and ranged from 20 to 44 years of age. Results: In total, 97.8% of subjects were seropositive for rubella-specific IgG antibodies, with a median titer of 40.56 IU/mL, suggesting a high degree of immunization; however, 2.2% of subjects were found to be seronegative. Interestingly, 25.1% of subjects were seropositive but had titers lower than 25 IU/mL, indicating either a population of low responders or individuals that could potentially be at risk of waning immunity. No significant associations or differences were found between RV-specific titers and demographic variables such as age, sex, or body mass index (BMI). Conclusions: A high rate of seropositivity for rubella was found among this young adult cohort, but a significant percent of the cohort had lower titers that may indicate poor initial vaccine response and potential risk if their antibody titers decline.
AB - Background: Although the administration of the measles-mumps-rubella (MMR) vaccine has been widespread in the United States for decades, gaps in vaccine coverage still persist for various reasons. The maintenance of herd immunity against rubella virus (RV) is important to controlling the spread and resurgence of rubella and congenital rubella syndrome. Methods: In this study, we sought to assess the seroprevalence of RV-specific antibodies in an adult population from a defined geographic area in Olmsted County, MN, and the surrounding municipalities, with relatively high vaccine coverage and no documented evidence of circulating RV in the past 24 years. Rubella-specific IgG antibodies were measured by ELISA in a large set of serum samples (n = 1393) obtained from the Mayo Clinic Biobank. This cohort was 80.2% female and ranged from 20 to 44 years of age. Results: In total, 97.8% of subjects were seropositive for rubella-specific IgG antibodies, with a median titer of 40.56 IU/mL, suggesting a high degree of immunization; however, 2.2% of subjects were found to be seronegative. Interestingly, 25.1% of subjects were seropositive but had titers lower than 25 IU/mL, indicating either a population of low responders or individuals that could potentially be at risk of waning immunity. No significant associations or differences were found between RV-specific titers and demographic variables such as age, sex, or body mass index (BMI). Conclusions: A high rate of seropositivity for rubella was found among this young adult cohort, but a significant percent of the cohort had lower titers that may indicate poor initial vaccine response and potential risk if their antibody titers decline.
KW - Antibodies
KW - Demographics
KW - MMR
KW - Measles-mumps-rubella
KW - Rubella
KW - Seroepidemiology
KW - Titer
UR - http://www.scopus.com/inward/record.url?scp=85065838735&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85065838735&partnerID=8YFLogxK
U2 - 10.1016/j.vaccine.2019.05.049
DO - 10.1016/j.vaccine.2019.05.049
M3 - Article
C2 - 31126859
AN - SCOPUS:85065838735
SN - 0264-410X
VL - 37
SP - 3876
EP - 3882
JO - Vaccine
JF - Vaccine
IS - 29
ER -